Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant
Petra Hoever, SL de Haas, Julia Winkler, et al.
Clinical Pharmacology & Therapeutics (2010) Vol. 87, Iss. 5, pp. 593-600
Closed Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

REM Sleep Instability – A New Pathway for Insomnia?
Dieter Riemann, Kai Spiegelhalder, Christoph Nissen, et al.
Pharmacopsychiatry (2012)
Closed Access | Times Cited: 215
Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal
Takeshi Sakurai, Michihiro Mieda
Trends in Pharmacological Sciences (2011) Vol. 32, Iss. 8, pp. 451-462
Open Access | Times Cited: 211
International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology
Anthony L. Gotter, Andrea L. Webber, Paul J. Coleman, et al.
Pharmacological Reviews (2012) Vol. 64, Iss. 3, pp. 389-420
Closed Access | Times Cited: 154
Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
Petra Hoever, Georg Dorffner, Heike Beneš, et al.
Clinical Pharmacology & Therapeutics (2012) Vol. 91, Iss. 6, pp. 975-985
Open Access | Times Cited: 122
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia
Anthony J. Roecker, Christopher D. Cox, Paul J. Coleman
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 2, pp. 504-530
Closed Access | Times Cited: 107
Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?
Daniël Hoyer, Laura H. Jacobson
Neuropeptides (2013) Vol. 47, Iss. 6, pp. 477-488
Closed Access | Times Cited: 107
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis
Almira Chabi, Ying Zhang, Saheeda Jackson, et al.
Cephalalgia (2014) Vol. 35, Iss. 5, pp. 379-388
Closed Access | Times Cited: 103
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
The Pictet-Spengler Reaction Updates Its Habits
Andrea Calcaterra, Laura Mangiardi, Giuliano Delle Monache, et al.
Molecules (2020) Vol. 25, Iss. 2, pp. 414-414
Open Access | Times Cited: 71
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Orexin (Hypocretin) Receptor Agonists and Antagonists for Treatment of Sleep Disorders
Michihiro Mieda, Takeshi Sakurai
CNS Drugs (2013) Vol. 27, Iss. 2, pp. 83-90
Closed Access | Times Cited: 98
Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia
Claudia Betschart, Samuel Hintermann, Dirk Behnke, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 19, pp. 7590-7607
Closed Access | Times Cited: 96
Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition
Jason M. Uslaner, Spencer J. Tye, Donnie Eddins, et al.
Science Translational Medicine (2013) Vol. 5, Iss. 179
Closed Access | Times Cited: 86
Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist
Yu Yoshida, Yoshimitsu Naoe, Taro Terauchi, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 11, pp. 4648-4664
Closed Access | Times Cited: 76
Selective orexin receptor antagonists
Terry P. Lebold, Pascal Bonaventure, Brock T. Shireman
Bioorganic & Medicinal Chemistry Letters (2013) Vol. 23, Iss. 17, pp. 4761-4769
Closed Access | Times Cited: 73
Orexin-1 receptor signalling in the prelimbic cortex and ventral tegmental area regulates cue-induced reinstatement of ethanol-seeking in iP rats
Robyn M. Brown, Andrezza K. Kim, Shaun Yon‐Seng Khoo, et al.
Addiction Biology (2015) Vol. 21, Iss. 3, pp. 603-612
Open Access | Times Cited: 64
Accelerated Development of the Dual Orexin Receptor Antagonist ACT‐541468: Integration of a Microtracer in a First‐in‐Human Study
Clemens Muehlan, Jules A. A. C. Heuberger, Pierre‐Éric Juif, et al.
Clinical Pharmacology & Therapeutics (2018) Vol. 104, Iss. 5, pp. 1022-1029
Open Access | Times Cited: 59
Orexin receptor antagonism: an ascending multiple-dose study with almorexant
Petra Hoever, Sanne Lysbet de Haas, Georg Dorffner, et al.
Journal of Psychopharmacology (2012) Vol. 26, Iss. 8, pp. 1071-1080
Closed Access | Times Cited: 68
Drugs for insomnia
Nava Zisapel
Expert Opinion on Emerging Drugs (2012) Vol. 17, Iss. 3, pp. 299-317
Closed Access | Times Cited: 65
Orexin deficiency and narcolepsy
Takeshi Sakurai
Current Opinion in Neurobiology (2013) Vol. 23, Iss. 5, pp. 760-766
Open Access | Times Cited: 62
Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?
Shaun Yon‐Seng Khoo, Robyn M. Brown
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 713-730
Open Access | Times Cited: 58
Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice
Keishi Etori, Yuki Saito, Natsuko Tsujino, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 53
Suvorexant for the treatment of insomnia
Laura H. Jacobson, Gabrielle E. Callander, Daniël Hoyer
Expert Review of Clinical Pharmacology (2014) Vol. 7, Iss. 6, pp. 711-730
Closed Access | Times Cited: 52
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia
Sander Brooks, Gabriël E. Jacobs, Peter de Boer, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 2, pp. 202-209
Closed Access | Times Cited: 52
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration
Clemens Muehlan, Sander Brooks, Rob Zuiker, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 7, pp. 847-857
Closed Access | Times Cited: 49
Page 1 - Next Page

Scroll to top